Tuberous sclerosis, also called tuberous sclerosis complex (TSC), is a rare genetic multisystem disorder characterized by the ...

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their ...

Asia Pacific Leads Next Wave of Sickle Cell Screening Adoption as Public Health Funding Expands Global Sickle Cell Anemia ...

The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

Overall, the life expectancy of patients with SCD is lower than that of persons without SCD. 1 However, life expectancy varies depending on the type of disease, treatments administered, and ...

Sickle Cell Disease (SCD) is an inherited genetic condition that causes red blood cells to assume a rigid, crescent-like shape. These malformed cells obstruct blood vessels, leading to severe pain and ...

The Council of Scientific and Industrial Research (CSIR) has made significant scientific and research gains in 2024, especially for breast cancer, sickle cell anaemia, and Parkinson's disease in ...

The CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB) and Regional Cancer Centre (RCC), Thiruvananthapuram developed a non-invasive blood test for early breast cancer detection. The low-cost ...

New Delhi, Dec 27 (IANS): The Council of Scientific and Industrial Research (CSIR) has made significant scientific and research gains in 2024, especially for breast cancer, sickle cell anaemia, and ...